|
|
Hydroxyurea
The Basics
- An Overview of Hydroxyurea (Regularly Updated)
- Hydroxyurea (November 8, 2007)
To read PDF, click here
From AIDS InfoNet
- Hydroxyurea (Hydrea) (August 15, 2006)
From AIDS Treatment Data Network
- Patient Information About Hydroxurea (Hydrea) (PDF) (October 2005)
From Bristol-Myers Squibb Company
- The Twisted Tale of Hydroxyurea, the On-Again, Off-Again HIV Drug (October 2004)
In POZ
- ddI, d4T and Hydroxyurea Side Effect Warning! (April 2000)
In Project Inform Perspective, from Project Inform
- Hydroxyurea -- Ever More Fascinating! (September 1998)
In Notes From the Underground, from PWA Health Group
- Help From Hydroxyurea (April 1998)
In HIV Newsline, from San Francisco General Hospital
- Hydroxyurea Fact Sheet (April 1998)
From Project Inform
- Drug Keeps Man HIV-Free (Spring 1998)
News about hydroxyurea.
In Women Alive Newsletter, from Women Alive
- The Hydroxyurea Steamroller (November 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Research
- Little-Noticed Ban of Little-Used Drug Triggers Little-Known Investigation (May 2004)
Dr. Paul C. Bellman, one of the first physicians ever to treat HIV-positive patients, questions the U.S. HIV treatment guidelines' stance against hydroxyurea.
In TAGline, from Treatment Action Group
- Hydroxyurea May Cut Sickle-Cell Death Rates (April 2, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Strategies to Prevent Loss of CD4+ and Onset of Resistance During Treatment Interruptions (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine and/or Hydroxyurea to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Hydroxyurea May Trigger Pancreatitis When Combined With Didanosine (May 2001)
In Body Positive, from Body Positive
- The Effect of Hydroxyurea on Intracellular Deoxy- and Dideoxynucleoside Triphosphate Ratios in Naive Subjects Receiving ZDV, ABC, 3TC+- NVP over 48 Weeks -- CHARM Phosphorylation Substudy (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Viral Resistance Results From the International, Multicenter, Randomized, Placebo-Controlled, 48-Week Study of Hydroxyurea or Placebo Combined With Efavirenz, Didanosine and Stavudine in Treatment-Naive and -Experienced Patients (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- STOP EARTH 4 Study: Structured Treatment Interruption With or Without Hydroxyurea (January 31, 2001)
From Project Inform
- Pancreatitis Associated With Hydroxyurea in Combination With Didanosine (January 13, 2001)
In British Medical Journal
- The QuadriVar Study: d4T/ddI/SaquinavirSGC/Nelfinavir/Hydroxyurea/IL-2 in Primary HIV-1 Infection -- Preliminary Results (September 18, 2000)
In The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Prospective, Multicenter Study of ddI Plus Hydroxyurea Plus Efavirenz Plus Protease Inhibitor Salvage Therapy. One-Year of Follow-Up. (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- The Effects of Hydroxyurea or Placebo Combined with Efavirenz, Didanosine, and Stavudine in Treatment of Naive and Experienced Patients: Preliminary 24-Week Results From the Third Study (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- STI Following 48 Weeks of HAART + Hydroxyurea During Acute Infection (April 2000)
In TAGline, from Treatment Action Group
- Hydroxyurea and Its Role in HIV Disease (September 26, 1999)
In The 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Phase I/II Dosing Study of Once-Daily Hydroxyurea Alone vs Didanosine Alone vs ddI + HU (February 9, 1999)
Summary by Donald L. Kaminsky, M.D.
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Phase I Study of Hydroxyurea in HIV-Infected Children Receiving Didanosine and/or Stavudine (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Phase I/II Dosing Study of Once-Daily Hydroxyurea Alone vs Didanosine Alone vs ddI + HU (February 2, 1999)
Summary by Kent Sepkowitz, M.D.
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Tailoring Drug Treatments With the Use of Hydroxyurea (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Treatment with d4T + ddI + Nelfinavir + Hydroxyurea for Early or Recent Primary HIV Infection (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Studies With Hydroxyurea Show Promising Results (August 31, 1998)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Hydroxyurea Studies (June 29 and July 2, 1998)
In The 12th International AIDS Conference, from The Body PRO
- Hydroxyurea -- More Information on the Antiretroviral Drug Without Antiviral Activity (June 29 and 30, 1998)
In The 12th International AIDS Conference, from The Body PRO
|
Advertisement
|
